Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa

(2016) Jens Kuhle et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study

(2016) Axel Petzold et al.   Multiple Sclerosis Journal

Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity

(2016) Jens Kuhle et al.   Multiple Sclerosis Journal

Neurofilament light chain level is a weak risk factor for the development of MS

(2016) Georgina Arrambide et al.   NEUROLOGY

Dynamic Response Genes in CD4+ T Cells Reveal a Network of Interactive Proteins that Classifies Disease Activity in Multiple Sclerosis

(2016) Sandra Hellberg et al.   Cell Reports

Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study

(2016) Axel Petzold et al.   Multiple Sclerosis Journal

Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity

(2016) Jens Kuhle et al.   Multiple Sclerosis Journal

Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients

(2015) Brit Fitzner et al.   AUTOIMMUNITY REVIEWS

Biomarkers in multiple sclerosis

(2015) William J. Housley et al.   CLINICAL IMMUNOLOGY

Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis

(2015) S Modvig et al.   Multiple Sclerosis Journal

The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level—NO

(2015) Georgina Arrambide et al.   Multiple Sclerosis Journal

The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level – YES

(2015) Jonatan Salzer   Multiple Sclerosis Journal

Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis

(2015) M Alba Mañé Martínez et al.   Multiple Sclerosis Journal

Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis

(2015) G Hinsinger et al.   Multiple Sclerosis Journal

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis

(2015) J. Kuhle et al.   NEUROLOGY

Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis

(2015) S Modvig et al.   Multiple Sclerosis Journal

The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level—NO

(2015) Georgina Arrambide et al.   Multiple Sclerosis Journal

The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level – YES

(2015) Jonatan Salzer   Multiple Sclerosis Journal

Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis

(2015) M Alba Mañé Martínez et al.   Multiple Sclerosis Journal

Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis

(2015) G Hinsinger et al.   Multiple Sclerosis Journal

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

(2015) Gavin Giovannoni et al.   Multiple Sclerosis and Related Disorders

Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction

(2015) Mattias Vågberg et al.   PLoS One

Biomarkers of Therapeutic Response in Multiple Sclerosis: Current Status

(2014) Violaine K. Harris et al.   Molecular Diagnosis & Therapy

Brain atrophy and lesion load predict long term disability in multiple sclerosis

(2013) Veronica Popescu et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

A comparative study of CSF neurofilament light and heavy chain protein in MS

(2013) Jens Kuhle et al.   Multiple Sclerosis Journal

CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis

(2012) Jeppe Romme Christensen et al.   Multiple Sclerosis Journal

Neurofilaments as biomarkers in multiple sclerosis

(2012) Charlotte E Teunissen et al.   Multiple Sclerosis Journal

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Indications of Th1 and Th17 responses in cerebrospinal fluid from patients with Lyme neuroborreliosis: a large retrospective study

(2011) Anna J Henningsson et al.   Journal of Neuroinflammation

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

Neurofilament light as a prognostic marker in multiple sclerosis

(2010) Jonatan Salzer et al.   Multiple Sclerosis Journal

Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis

(2010) Lars Börnsen et al.   Multiple Sclerosis Journal

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course

(2010) Mohsen Khademi et al.   Multiple Sclerosis Journal